InvestorsHub Logo
Followers 0
Posts 178
Boards Moderated 0
Alias Born 12/04/2013

Re: None

Monday, 05/08/2017 3:13:13 PM

Monday, May 08, 2017 3:13:13 PM

Post# of 8529
Q1 results time. So what are we reckoning? Disappointing royalty growth (yet again) suggesting that Shire isn't promoting HyQ anywhere in the world and that Roche is peaking on SC Mabthera and Herceptin in Europe despite all the spin. And the loss will be enormous due to completely out of control costs of PEGPH20 trials and for a way too expensive management structure. No new partnership deals, no news on early approval of PAG, no news on any of the other Enhanze partnership products and no news on when the next fund raising will be - although we all know it will be after SC Mabthera is approved by the FDA. All in all a typical HALO quarter.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News